Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment

Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ growth stocks to buy and hold forever. On April 9, Invivyd announced significant progress in its REVOLUTION clinical program, specifically regarding VYD2311, a monoclonal antibody candidate for COVID-19 prevention. A pre-specified analysis of the Phase 3 DECLARATION study revealed that accumulated clinical events already provide sufficient statistical power to support high-end efficacy targets.

Consequently, Invivyd has triggered a conservative upsizing of the study by ~500 subjects to ensure robust data across various scenarios. This adjustment is expected to shift the timing of top-line results slightly, moving from mid-year guidance to Q3 2026. In addition to its COVID-19 efforts, the company revealed the discovery and advancement of VMS063, a novel monoclonal antibody for the treatment and prevention of measles.

Designed to be a first-in-class precision therapy, VMS063 targets the measles Fusion protein to prevent cell entry, demonstrating high potency against circulating lineages in laboratory assays. With US measles incidence reaching decade-high levels, Invivyd Inc. (NASDAQ:IVVD) is fast-tracking VMS063 toward regulatory outreach and IND-enabling studies, with a target for IND readiness in late 2026.

Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform

Invivyd Inc. (NASDAQ:IVVD) develops next‑generation antibody drugs aimed at long‑lasting effectiveness against evolving viruses, using a proprietary platform to deliver durable therapies.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.